Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma Journal Article

Fulltext large Open access2  

Authors: Mondello, P.; Derenzini, E.; Asgari, Z.; Philip, J.; Brea, E. J.; Seshan, V.; Hendrickson, R. C.; de Stanchina, E.; Scheinberg, D. A.; Younes, A.
Article Title: Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma
Abstract: Phosphoinositide 3-kinase (PI3K) and Myc are known to cooperate in promoting the survival and growth of a variety of B-cell lymphomas. While currently there are no small molecule inhibitors of Myc protein, histone deacetylase (HDAC) inhibitors have been shown to reduce levels of Myc protein by suppressing its transcription. We assessed the efficacy of CUDC-907, a new rationally designed dual inhibitor of PI3K and HDACs, in a panel of lymphoma cell lines. CUDC-907 treatment resulted in a dose- and time-dependent growth inhibition and cell death of DLBCL cell lines, irrespective of the cell of origin. CUDC-907 treatment down-regulated the phosphorylation of PI3K downstream targets, including AKT, PRAS40, S6, and 4EBP1, increased histone 3 acetylation, and decreased Myc protein levels. SILAC-based quantitative mass spectrometry demonstrated that CUDC-907 treatment decreased the protein levels of several components of the B cell receptor (BCR) and Toll like receptor (TLR) pathways, including BTK, SYK, and MyD88 proteins. These cellular changes were associated with an inhibition of NF-kB activation. CUDC-907 demonstrated in vivo efficacy with no significant toxicity in a human DLBCL xenograft mouse model. Collectively, these data provide a mechanistic rationale for evaluating CUDC-907 for the treatment of patients with Myc and PI3K-dependent lymphomas.
Keywords: pi3k; myc; dlbcl; bcr pathway
Journal Title: Oncotarget
Volume: 8
Issue: 8
ISSN: 1949-2553
Publisher: Impact Journals  
Date Published: 2017-02-21
Start Page: 14017
End Page: 14028
Language: English
DOI: 10.18632/oncotarget.14876
PROVIDER: scopus
PUBMED: 28147336
PMCID: PMC5355158
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85013413526&doi=10.18632%2foncotarget.14876&partnerID=40&md5=2b2e2d3f9c4b05a6da44dea5662ae2de
Notes: Article -- Export Date: 3 April 2017 -- Source: Scopus
Altmetric Score
What is Altmetric?
MSK Authors
  1. Venkatraman Ennapadam Seshan
    282 Seshan
  2. David Scheinberg
    379 Scheinberg
  3. Elisa De Stanchina
    130 De Stanchina
  4. Ronald Charles Hendrickson
    29 Hendrickson
  5. Zahra Asgari
    6 Asgari
  6. John Philip
    20 Philip
  7. Anas Younes
    187 Younes
  8. Enrico Derenzini
    6 Derenzini
  9. Patrizia Mondello
    17 Mondello
  10. Elliott Joseph Brea
    13 Brea
Related MSK Work